Sage Therapeutics (SAGE) announced that Biogen (BIIB) has terminated its rights under the collaboration and license agreement with Sage specific to the SAGE-324 program. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor, or ET, and discontinued further clinical development of SAGE-324 in ET. Sage and Biogen will continue to partner on Zurzuvae the first and only FDA-approved oral treatment for women with postpartum depression, or PPD, and will continue to work on their shared vision to help women suffering from PPD. Under the terms of the collaboration and license agreement, the termination will be effective on February 17, 2025, and Sage will resume full ownership of the SAGE-324 asset at that time. Sage plans to continue to evaluate other potential indications, if any, for SAGE-324.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics files automatic mixed securities shelf
- Sage Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP for More Information – SAGE
- Sage Therapeutics price target lowered to $13 from $18 at Truist
- Closing Bell Movers: Dutch Bros melts over 20% on slower unit growth
- Sage Therapeutics price target lowered to $9 from $17 at Canaccord